| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/30/2014 | WO2014017593A1 Adhesive patch and production method therefor |
| 01/30/2014 | WO2014017573A1 Composition for agent for external use |
| 01/30/2014 | WO2014017507A1 Solid pharmaceutical preparation |
| 01/30/2014 | WO2014017411A1 External preparation for treating trichophytosis unguium |
| 01/30/2014 | WO2014016917A1 Acidic liquid nutrient |
| 01/30/2014 | WO2014016850A1 Stable pharmaceutical composition of fluindione |
| 01/30/2014 | WO2014016848A2 Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof |
| 01/30/2014 | WO2014016754A2 Pharmaceutical compositions of proton pump inhibitor |
| 01/30/2014 | WO2014016671A2 Formulations and methods of manufacturing formulations for use in colonic evacuation |
| 01/30/2014 | WO2014016653A1 Pharmaceutical composition comprising diamorphine for intranasal administration |
| 01/30/2014 | WO2014016428A1 Opioid formulations |
| 01/30/2014 | WO2014016396A1 Oral dosage forms for modified release comprising ruxolitinib |
| 01/30/2014 | WO2014016380A1 Chondroitin complexes for transcutaneous absorption |
| 01/30/2014 | WO2014016371A1 Micronized aleglitazar |
| 01/30/2014 | WO2014016370A1 Amorphous aleglitazar |
| 01/30/2014 | WO2014016369A1 Pharmaceutical formulation comprising aleglitazar and complexing agent |
| 01/30/2014 | WO2014016367A1 Composition of microcapsules with a silica shell and a method for their preparation |
| 01/30/2014 | WO2014016252A1 New treatment of fish with a nanosus pens ion of lufenuron or hexaflumuron |
| 01/30/2014 | WO2014015992A1 Medicinal clay preparation |
| 01/30/2014 | WO2014015672A1 Compound preparation of lercanidipine and atorvastatin |
| 01/30/2014 | WO2014015507A1 Application of shengui capsule in preparing antithrombotic drugs |
| 01/30/2014 | WO2014015444A1 Use of isotonic physiological electrolysis water for intravenous injection for combatting systemic viroses and bacterioses by means of oxidative radicals |
| 01/30/2014 | WO2014015443A1 Use of electrolysis water produced with the aid of diamond electrodes for the hydration, firming and care of skin, for the treatment of dermatoses, sunburn and general wounds |
| 01/30/2014 | WO2014015436A1 Apparatus and method of controlling the rate of nicotine delivery |
| 01/30/2014 | WO2014015422A1 Cellulose-based nanoparticles for drug delivery |
| 01/30/2014 | WO2013183062A3 Palatable formulations of ibuprofen |
| 01/30/2014 | WO2013168179A3 Controlled release pharmaceutical formulations of antiviral agents |
| 01/30/2014 | WO2013164121A4 Aqueous dispersions of hydroxypropyl methylcellulose acetate succinate (hpmcas) |
| 01/30/2014 | WO2013153349A3 Pharmaceutical composition comprising arformoterol and fluticasone furoate |
| 01/30/2014 | WO2013144341A9 Microsphere compositions, preparation method and applications thereof |
| 01/30/2014 | WO2013105101A8 Solid lipid nanoparticles entrapping hydrophilic/ amphiphilic drug and a process for preparing the same |
| 01/30/2014 | WO2012170889A8 Cleavable lipids |
| 01/30/2014 | WO2012160223A9 Pharmaceutical composition |
| 01/30/2014 | US20140031435 Propofol compositions and methods for reducing pain associated with propofol injection |
| 01/30/2014 | US20140031408 Biodegradable Intravitreal Tyrosine Kinase Implants |
| 01/30/2014 | US20140031397 Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient |
| 01/30/2014 | US20140031396 Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient |
| 01/30/2014 | US20140031381 Tamper resistant dosage forms |
| 01/30/2014 | US20140031366 Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds |
| 01/30/2014 | US20140031312 Compositions and formulations of glucosamine for transdermal and transmucosal administration |
| 01/30/2014 | US20140031298 Compositions and Methods for Localized Therapy of the Eye |
| 01/30/2014 | US20140031281 Polymer-based sustained release device |
| 01/30/2014 | US20140030523 Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
| 01/30/2014 | US20140030352 Nanodispersion |
| 01/30/2014 | US20140030351 Therapeutic Polymeric Nanoparticle Compositions with High Glass Transition Temperature or High Molecular Weight Copolymers |
| 01/30/2014 | US20140030350 Drug Delivery Systems |
| 01/30/2014 | US20140030349 Granules in liquid dosage form |
| 01/30/2014 | US20140030348 Dosage forms for oral administration and methods of treatment using the same |
| 01/30/2014 | US20140030347 Mass production of ready-to-use suspensions of fibrinogen-coated albumin spheres for the treatment of thrombocytopenic patients |
| 01/30/2014 | US20140030346 Disintegrable core particle for pharmaceutical preparation |
| 01/30/2014 | US20140030343 Formulations and Methods for Attenuating Respiratory Depression Induced by Opioid Overdose |
| 01/30/2014 | US20140030342 Process for producing an immunogenic composition containing tetanus toxoid |
| 01/30/2014 | US20140030340 Preparation of drug particles using evaporation precipitation into aqueous solutions |
| 01/30/2014 | US20140030338 Product |
| 01/30/2014 | US20140030337 Composition for a topical ophthalmic clear colloidal liquid which undergoes a liquid-gel phase transition in the eye |
| 01/30/2014 | US20140030336 Pharmaceutical composition for the treatment of acute disorders |
| 01/30/2014 | US20140030332 Chemosensory Receptor Ligand-Based Therapies |
| 01/30/2014 | US20140030331 Method of treating multiple sclerosis |
| 01/30/2014 | US20140030330 Dosage forms of apixaban |
| 01/30/2014 | US20140030329 Methods for Treating Insomnia |
| 01/30/2014 | US20140030328 Dual release oral tablet compositions of dexlansoprazole |
| 01/30/2014 | US20140030327 Tamper resistant dosage forms |
| 01/30/2014 | US20140030326 Effervescent formulations comprising dexketoprofen |
| 01/30/2014 | US20140030325 Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid |
| 01/30/2014 | US20140030323 Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation |
| 01/30/2014 | US20140030322 Pharmaceutical compositions |
| 01/30/2014 | US20140030321 Solid pharmaceutical composition |
| 01/30/2014 | US20140030316 Transdermal administration of fentanyl and analogs thereof |
| 01/30/2014 | US20140030315 Nanofiber scaffolds for biological structures |
| 01/30/2014 | US20140030313 Treatment of menstrual pain and excessive menstrual blood loss by intravaginal administration of a low dose of antifibrinolytic or hemostatic agent in combination with non-steroidal anti-inflammatory drug |
| 01/30/2014 | US20140030311 Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof |
| 01/30/2014 | US20140030310 Implant and method for manufacturing same |
| 01/30/2014 | US20140030249 Pharmaceutical Compositions |
| 01/30/2014 | US20140030248 Injection paradigm for administration of botulinum toxins |
| 01/30/2014 | US20140030209 Topical liquid agent for the treatment of dermatophytosis |
| 01/30/2014 | US20140026905 Apparatus and method of controlling the rate of nicotine delivery |
| 01/30/2014 | DE102012014688A1 Combination formulation useful for treating e.g. dry, damaged or irritated skin, skin diseases e.g. psoriasis, eczema and acne, comprises first composition comprising chitosan and second composition comprising oil, and an active ingredient |
| 01/30/2014 | CA2875818A1 Pharmaceutical formulation for bedwetting and method of use thereof |
| 01/29/2014 | EP2689836A1 Composition of microcapsules with a silica shell and a method for preparing them |
| 01/29/2014 | EP2689785A1 Method for generating dry vaccine powder formulation for intranasal delivery |
| 01/29/2014 | EP2689775A1 Cochleate with only one mamp |
| 01/29/2014 | EP2689774A1 Reversely thermo-reversible hydrogel compositions |
| 01/29/2014 | EP2688651A1 Composition containing a cellulose, a vegetable oil and a volatile solvent, and use thereof as a dressing |
| 01/29/2014 | EP2688650A1 Film-forming composition containing a sun filter, and use thereof for the treatment of scars |
| 01/29/2014 | EP2688639A2 System and method for biphasic transdermal iontophoretic delivery of therapeutic agents |
| 01/29/2014 | EP2688575A2 Lithium compositions |
| 01/29/2014 | EP2688564A2 Calcium supplement |
| 01/29/2014 | EP2688562A2 Mesh enclosed tissue constructs |
| 01/29/2014 | EP2688561A2 Transdermal compositions comprising an active agent layer and an active agent conversion layer |
| 01/29/2014 | EP2688560A2 A composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative |
| 01/29/2014 | EP2688559A2 Swallowable medication capsule |
| 01/29/2014 | EP2688558A2 Oral complex composition comprising omega-3 fatty acid ester and hmg-coa reductase inhibitor |
| 01/29/2014 | EP2688557A1 Methods and compositions for treatment of attention deficit disorder |
| 01/29/2014 | EP2688556A2 Controlled release pharmaceutical dosage forms |
| 01/29/2014 | EP2688555A1 Solid ambroxol-containing preparation |
| 01/29/2014 | EP2688554A2 Optimised preparations of highly adaptable aggregates |
| 01/29/2014 | EP2688553A1 Pharmaceutical composition for use in nasal administration containing corticoid, and a quinolone or fusidic acid |
| 01/29/2014 | EP2688552A1 A pharmaceutical composition for treating a disease in the oral cavity comprising rebamipide |
| 01/29/2014 | EP2688551A1 A composition and method |
| 01/29/2014 | EP2574343B1 Compound for skin application and use of same |